Remi Barbier

This profile gathers the share dealings of Remi Barbier in Filana Therapeutics, Inc., where the filings describe the role as chief executive. Between 1 May 2002 and 24 May 2023, the trades on record add up to 205 filings.

In open-market terms, that means 7 purchases worth €636k on one side and 149 sales worth €13.5M on the other. The totals do not cover 1 filing with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 12 share grants and 11 option exercises.

A typical purchase (the median) is worth €26k. Of 4 purchases, 4 formed part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster. Looking at 5 purchases old enough to measure, the stock rose over the following 90 days in 40% of cases; the median change was -20.7%. These figures describe past trades and do not predict future prices.

The newest entry dates from 25 May 2023: a share grant of €224k, in Filana Therapeutics, Inc. The most recent open-market purchase was published on 24 September 2020, 2,236 days ago. The median gap between a trade and its publication by SEC (Form 4) is 1 day. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.